Tex. Health & Safety Code § 489.051 · Subchapter B. ACCESS TO INVESTIGATIONAL DRUGS, BIOLOGICAL PRODUCTS, AND DEVICES FOR PATIENTS WITH TERMINAL ILLNESSES
PATIENT ELIGIBILITY.
Text — Current through the 89th 2nd Called Legislative Session, 2025
A patient is eligible to access and use an investigational drug, biological product, or device under this chapter if:
(1) the patient has a terminal illness, attested to by the patient's treating physician; and
(2) the patient's physician:
(A) in consultation with the patient, has considered all other treatment options currently approved by the United States Food and Drug Administration and determined that those treatment options are unavailable or unlikely to prolong the patient's life; and
(B) has recommended or prescribed in writing that the patient use a specific class of investigational drug, biological product, or device.
Notes and commentary — not statutory text
History
Added by Acts 2015, 84th Leg., R.S., Ch. 502 (H.B. 21), Sec. 2, eff. June 16, 2015.
Source of truth
- Edition
- Current through the 89th 2nd Called Legislative Session, 2025
- Official file
- https://statutes.capitol.texas.gov/Docs/HS/htm/HS.489.htm
- Text hash
- sha256 9a3aae01e686abbc89a478c1137b89c12a39c050f5495e7a077f1e31430d5e98
- Composed by
- compose_tx.py 2026-10-05: the Legislative Council's chapter files read in document order; verify_tx.py's independent reading (lxml DOM walk) agrees character for character
Procedural information only. Not legal advice and not a substitute for the advice of an attorney. Confirm the current text with the official publisher before relying on it.